UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years

Virchows Archiv : an international journal of pathology, 2023-12, Vol.483 (6), p.873-878

2023

Volltextzugriff (PDF)

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Leukemia, 2018-08, Vol.32 (8), p.1799-1803

2018

Volltextzugriff (PDF)

CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL

Hematological oncology, 2019-06, Vol.37 (S2), p.400-401

2019

Volltextzugriff (PDF)

GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATION

Hematological oncology, 2023-06, Vol.41 (S2), p.63-65

2023

Volltextzugriff (PDF)

Isolated amyloidosis of the gastro-intestinal tract

Acta gastro-enterologica belgica, 2022-01, Vol.85 (1), p.80-84

2022

Volltextzugriff (PDF)

HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATE

Hematological oncology, 2023-06, Vol.41 (S2), p.207-208

2023

Volltextzugriff (PDF)

When hematochezia becomes a red herring

Acta gastro-enterologica belgica, 2021-10, Vol.84 (4), p.684-684

2021

Volltextzugriff (PDF)

COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA

Hematological oncology, 2023-06, Vol.41 (S2), p.136-138

2023

Volltextzugriff (PDF)

Diagnostically challenging human papillomavirus-associated primary squamous cell carcinoma of the rectum with metastasis in both ovaries: a case report

Journal of medical case reports, 2020-02, Vol.14 (1), p.30-7, Article 30

2020

Volltextzugriff (PDF)

Outcome in critically ill patients with allogeneic BM or peripheral haematopoietic SCT: a single-centre experience

Bone marrow transplantation (Basingstoke), 2011-09, Vol.46 (9), p.1186-1191

2011

Volltextzugriff (PDF)

Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer

European journal of cancer (1990), 2003-11, Vol.39 (17), p.2499-2505

2003

Volltextzugriff (PDF)

GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) PATIENTS

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis

Blood, 2001-11, Vol.98 (9), p.2720-2725

2001

Volltextzugriff (PDF)

MYELOMA THERAPY: PURSUING THE PLASMA CELL

Acta Clinica Belgica, 2010-06, Vol.65 (3), p.205-206

Offner, F.

2010

Volltextzugriff (PDF)

Adverse effects of polyvinylidene fluoride-coated polypropylene mesh used for laparoscopic intraperitoneal onlay repair of incisional hernia

British journal of surgery, 2010-07, Vol.97 (7), p.1140-1145

2010

Volltextzugriff (PDF)

FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R‐DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT

HemaSphere, 2022-06, Vol.6 (Suppl), p.1101-1102

2022

Volltextzugriff (PDF)

P1214: SUBCUTANEOUS EPCORITAMAB + R‐CHOP FOR FIRST‐LINE TREATMENT OF PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA: PHASE 1/2 UPDATE

HemaSphere, 2022-06, Vol.6 (Suppl), p.1100-1101

2022

Volltextzugriff (PDF)

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Journal of clinical oncology, 2021-06, Vol.39 (18), p.1959-1970

2021

Volltextzugriff (PDF)

EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Hematological oncology, 2019-06, Vol.37 (S2), p.214-216

2019

Volltextzugriff (PDF)

Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles

Leukemia, 2011-05, Vol.25 (5), p.883-888

2011

Volltextzugriff (PDF)

AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO

Hematological oncology, 2019-06, Vol.37 (S2), p.227-229

2019

Volltextzugriff (PDF)

AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS

Hematological oncology, 2019-06, Vol.37 (S2), p.114-115

2019

Volltextzugriff (PDF)

S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS

HemaSphere, 2022-06, Vol.6, p.121-122

2022

Volltextzugriff (PDF)

1 – 25 von 705

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(624)
Mit Volltextzugriff
(562)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(383)
Life Sciences & Biomedicine
(337)
Humans
(321)
Biological And Medical Sciences
(204)
Female
(181)
Male
(174)
Medical Sciences
(169)
Adult
(99)
Animals
(88)
Child
(86)
Middle Aged
(80)
Adolescent
(75)
Aged
(64)
Child, Preschool
(62)
Immunology
(58)
Amino Acid Sequence
(52)
Fundamental And Applied Biological Sciences. Psychology
(45)
Mice
(40)
Molecular Sequence Data
(40)
Surgery
(40)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(409)
EZB Electronic Journals Library
(292)
Ingenta
(276)
Journals@OVID
(265)
NUS Single-Journal Subscriptions
(202)
Access via ScienceDirect (Elsevier)
(128)
Wiley-Blackwell Journals
(99)
SpringerLink
(99)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(89)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(82)
IngentaConnect Journals
(72)
Wiley Online Library
(72)
Oxford Journals
(44)
Oxford Journals 2020 Medicine
(28)
JSTOR All Journals
(25)
Taylor & Francis Online
(21)
Peeters Online Journals
(20)
Taylor & Francis
(20)
Nature Journals Online
(18)
Nexis Uni
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL

GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATION

Isolated amyloidosis of the gastro-intestinal tract

HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATE

When hematochezia becomes a red herring

COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA

Diagnostically challenging human papillomavirus-associated primary squamous cell carcinoma of the rectum with metastasis in both ovaries: a case report

Outcome in critically ill patients with allogeneic BM or peripheral haematopoietic SCT: a single-centre experience

Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer

GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) PATIENTS

Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis

MYELOMA THERAPY: PURSUING THE PLASMA CELL

Adverse effects of polyvinylidene fluoride-coated polypropylene mesh used for laparoscopic intraperitoneal onlay repair of incisional hernia

FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2

P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R‐DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT

P1214: SUBCUTANEOUS EPCORITAMAB + R‐CHOP FOR FIRST‐LINE TREATMENT OF PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA: PHASE 1/2 UPDATE

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles

AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO

AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS

S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS

PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLECLEUCEL (TISA‐CEL) INFUSION IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

Suchergebnisse filtern